申请人:Senju Pharmaceutical Co., Ltd.
公开号:US05635505A1
公开(公告)日:1997-06-03
A 1,4-benzoxazine-2-acetic acid compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, a method for production thereof, and a pharmaceutical composition, an aldose reductase inhibitor and an agent for the prevention and/or treatment of the complications of diabetes, which contain the same. The compound (I) of the present invention and pharmaceutically acceptable salts thereof have aldose reductase inhibitory action and are superior in safety. Accordingly, they are useful as an agent for the prevention and/or treatment of the complications of diabetes such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis.
本发明涉及一种具有式(I)结构的1,4-苯并噁嗪-2-乙酸化合物##STR1##,其中每个符号的定义如说明书中所述,其药学上可接受的盐,其制备方法,以及含有该化合物的药物组合物、醛糖还原酶抑制剂和用于预防和/或治疗糖尿病并发症的药物。本发明的化合物(I)及其药学上可接受的盐具有醛糖还原酶抑制作用,且安全性优越。因此,它们可作为预防和/或治疗糖尿病并发症的药物,如角膜损伤愈合不良、白内障、神经病变、视网膜病变和肾病,特别是白内障和神经病变。